Lung cancer research at #ASCO22: Non-small cell lung cancer's with KRAS mutation respond to experimenal drug adagrasib which also shows activity in brain metastasis. Dana-Farber's Pasi Janne, Md, PhD, is senior author and explains more. Press release here: https://www.dana-farber.org/newsroom/news-releases/2022/targeted-drug-achieves-43--response-rate-in-kras-mutated-lung-cancer/ Video published June 4, 2022.